The Different Ways Ketamine Is Given for Depression
· Updated November 2026 · Aazaz Haq, MD
Ketamine for depression can be given into a vein, into a muscle, through the nose, or by mouth. People see all four advertised and reasonably ask which is best. The route changes how much medicine reaches the brain, how fast, and how predictably. Here is how I think about each one.
The short answer
Ketamine can be given by IV, by injection into a muscle, as a nasal spray, or by mouth. IV and IM deliver the most predictable doses; Spravato is the FDA-approved nasal form; oral ketamine is the least predictable. We offer IV, IM and Spravato, always under supervision, and help each person choose.
Intravenous (IV)
IV ketamine is a slow drip, usually over about 40 minutes, dosed by body weight. All of the medicine reaches the bloodstream, and we can slow or stop the drip if the experience becomes too intense. It has the most research behind it for depression, going back to studies in 2000 and 2006.
Intramuscular (IM)
IM ketamine is a single injection, usually in the shoulder. About 93% of the dose is absorbed, so it is nearly as precise as IV. It comes on faster and avoids an IV line. Research on IM ketamine for depression is smaller than for IV, but it is a reasonable, well-understood option in a monitored setting.
Nasal spray
There are two kinds. Spravato (esketamine) is FDA-approved, delivered by a device in fixed doses, and given only in certified clinics with two hours of monitoring. Compounded ketamine nasal sprays are not FDA-approved for depression, and absorption through the nose can vary from dose to dose. I explain the difference in more detail in Intranasal Ketamine: What Patients Should Know.
Oral and lozenges
Ketamine taken by mouth is largely broken down by the liver before it reaches the brain, and absorption varies a lot between people. Lozenges (troches) dissolve slowly, so the effect is gentler and longer. Some ketamine-assisted psychotherapists use them at lower doses, and several telehealth companies ship them for use at home.
I am very conservative about at-home ketamine. The FDA has warned that compounded ketamine used without a health care provider present carries added risk, including slowed breathing. Ketamine can also be misused.
What we use and why
At McLean NTC we offer IV ketamine, IM ketamine and Spravato, all in a supervised setting. We help each patient choose based on their needs, coverage and comfort:
- Spravato is usually covered by insurance.
- IV and IM ketamine are self-pay ($400 per treatment at our clinic, with payment plans), and the evidence suggests IV may work somewhat faster.
- IM avoids an IV line; IV can be slowed down.
The feeling during treatment is not the goal. Improvement in your symptoms and daily life over the following weeks is.
If you would like help sorting out which route fits you, request a consultation call.
Questions I hear often
Is one route more effective than the others?
IV ketamine has the most research for depression. One observational study suggested IV ketamine may work somewhat faster than Spravato, but patients were not randomly assigned, so it does not settle the question. Intramuscular ketamine delivers a similar amount of medicine to IV. Oral and lozenge forms are less predictable.
Why don't you prescribe ketamine to take at home?
Because I believe supervision is part of what makes this treatment safe. Monitoring blood pressure, watching for sedation, and controlling access to a medicine that can be misused are easier to do well in a clinic. Some practices do prescribe at home, and I understand the reasons in some settings, but it is not how we practice.
Can I change routes during treatment?
Yes. If IV is uncomfortable, IM may suit you better. If insurance coverage changes, Spravato may become the practical choice. We adjust as needed.
What stays the same, whatever the route
- A psychiatric evaluation first, including a careful look at substance use history.
- Blood pressure checks before each treatment.
- Monitoring until a clinician decides you are ready to leave.
- A ride home and no driving until the next day.
- Regular measurement of your symptoms, so we know whether it is helping.
References
- Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000. PubMed
- Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006. PubMed
- Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982. PubMed
- Meisner RC, et al. Repeated ketamine infusion versus intranasal esketamine in treatment-resistant depression: a retrospective chart review. J Clin Psychiatry. 2025. Source